22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional…
MICROB-PREDICT and DECISION are inviting the liver community to attend their half-day online symposium, Management of Acute-on-chronic Liver Failure, on 2 September 2021. This event is timed to precede EASL’s School of Hepatology, taking place 3–4 September, in Frankfurt, Germany,…
Researchers from EF Clif identify the causes that precipitate the onset of the most serious stage of cirrhosis: the syndrome of Acute-On-Chronic Liver Failure (ACLF). Barcelona, December 9, 2020 – A new investigation of the PREDICT study, which was led and…
Researchers at EF Clif identify three different clinical courses for the first time, in patients with acute decompensated cirrhosis without acute-on-chronic liver failure (ACLF). July 14, 2020 – A clinical study led by the European Foundation for the Study of…
According to a study conducted by the EF-Clif published in Gastroenterology This study has shown for the first time that the administration of albumin at high doses has an immunomodulatory effect both in the short (INFECIR-2) and long-term (Pilot-PRECIOSA) in…
SCIENTIFIC PRESS RELEASE Developing personalised targets for treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) Barcelona, Spain - An EU Horizon 2020-financed project investigating methods to better understand the role of the microbiome to help stratify patient health care…
